Secukinumab injection for severe erythrodermic psoriasis
Part of Immune system & allergy, Skin clinical trials.
This study tests a medicine called secukinumab, given as an injection, to see if it helps people with severe erythrodermic psoriasis — a type of psoriasis that covers most of the body with redness and scaling. The goal is to improve skin symptoms and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have erythrodermic psoriasis, meaning redness, scaling, and itching covering more than 90% of your body.
- Your skin condition must be caused by psoriasis, not another illness.
- You cannot have diabetes or a weakened immune system.
- You cannot be pregnant or breastfeeding, and you must not be allergic to the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well a biologic medication works and what happens when it is stopped in adults with moderate-to-severe plaque psoriasis. It may help you find a treatment that controls your symptoms and also informs you about managing your condition.
This study tests a drug called secukinumab (given through an IV) in children with juvenile psoriatic arthritis. The goal is to see how well it works and if it's safe over time, for up to 6 years.
This study looks at how well secukinumab works for psoriasis patients who also have a type of fatty liver disease called MASLD. It may help doctors understand if this treatment is a good option for people with both conditions.
This study tests whether applying secukinumab as a topical cream or as a subcutaneous injection is more effective and safer for treating hidradenitis suppurativa (a skin condition causing painful lumps). It aims to find a better way to manage symptoms in people whose condition has not improved with standard treatments.
This trial studies whether secukinumab (a targeted medicine given by injection) can reduce symptoms and disease activity in adults with active ankylosing spondylitis. You may be considered if other common anti-inflammatory medicines have not worked well enough or you could not take them.
This study compares two biologic medications, ixekizumab and secukinumab, to see which works better for psoriasis in people aged 70 and older. Both drugs are given as injections and aim to reduce skin symptoms and improve quality of life.
Hear when a new Erythrodermic Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.